The stock of Akero Therapeutics Inc (AKRO) has gone up by 4.79% for the week, with a 11.47% rise in the past month and a 25.38% rise in the past quarter. The volatility ratio for the week is 3.51%, and the volatility levels for the past 30 days are 4.37% for AKRO. The simple moving average for the last 20 days is 9.20% for AKRO stock, with a simple moving average of 24.14% for the last 200 days.
Is It Worth Investing in Akero Therapeutics Inc (NASDAQ: AKRO) Right Now?
Company’s 36-month beta value is -0.26.Analysts have differing opinions on the stock, with 8 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AKRO is 58.09M, and currently, short sellers hold a 12.33% ratio of that floaft. The average trading volume of AKRO on September 27, 2024 was 624.20K shares.
AKRO) stock’s latest price update
Akero Therapeutics Inc (NASDAQ: AKRO)’s stock price has plunge by 4.79relation to previous closing price of 28.00. Nevertheless, the company has seen a 4.79% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2024-09-20 that Akero Therapeutics’ Efruxifermin (EFX) showed strong results in pre-cirrhotic MASH, but failed in cirrhotic MASH, impacting stock performance. The MASH market is highly competitive with many pipeline drugs and one approved drug, resmetirom, creating significant risk for AKRO. Akero has a solid cash runway until 2027, providing financial stability for ongoing trials and potential future data releases.
Analysts’ Opinion of AKRO
Many brokerage firms have already submitted their reports for AKRO stocks, with BofA Securities repeating the rating for AKRO by listing it as a “Neutral.” The predicted price for AKRO in the upcoming period, according to BofA Securities is $30 based on the research report published on April 22, 2024 of the current year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see AKRO reach a price target of $69. The rating they have provided for AKRO stocks is “Overweight” according to the report published on September 19th, 2023.
UBS gave a rating of “Buy” to AKRO, setting the target price at $83 in the report published on August 28th of the previous year.
AKRO Trading at 11.25% from the 50-Day Moving Average
After a stumble in the market that brought AKRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.74% of loss for the given period.
Volatility was left at 4.37%, however, over the last 30 days, the volatility rate increased by 3.51%, as shares surge +10.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.35% upper at present.
During the last 5 trading sessions, AKRO rose by +4.79%, which changed the moving average for the period of 200-days by +47.66% in comparison to the 20-day moving average, which settled at $27.00. In addition, Akero Therapeutics Inc saw 25.65% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKRO starting from Yale Catriona, who sale 5,500 shares at the price of $27.65 back on Sep 20 ’24. After this action, Yale Catriona now owns 75,294 shares of Akero Therapeutics Inc, valued at $152,086 using the latest closing price.
Yale Catriona, the Chief Development Officer of Akero Therapeutics Inc, sale 3,871 shares at $27.56 during a trade that took place back on Sep 18 ’24, which means that Yale Catriona is holding 75,294 shares at $106,685 based on the most recent closing price.
Stock Fundamentals for AKRO
Current profitability levels for the company are sitting at:
- -824.59 for the present operating margin
- 0.97 for the gross margin
The net margin for Akero Therapeutics Inc stands at -718.93. The total capital return value is set at -0.28. Equity return is now at value -28.87, with -26.71 for asset returns.
Based on Akero Therapeutics Inc (AKRO), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -5.37. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -58.44.
Currently, EBITDA for the company is -172.84 million with net debt to EBITDA at 1.21. When we switch over and look at the enterprise to sales, we see a ratio of 6207.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 24.89.
Conclusion
In a nutshell, Akero Therapeutics Inc (AKRO) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
